A natural CYP2B6 TATA box polymorphism (-82T→C) leading to enhanced transcription and relocation of the transcriptional start site

Molecular Pharmacology

Volumn 67, Issue 5, 2005, Pages 1772-1782

  Zukunft, Jörg ^a   Lang, Thomas ^b,e   Richter, Tanja ^a   Hirsch Ernst, Karen I ^c   Nussler, Andreas K ^d   Klein, Kathrin ^a   Schwab, Matthias ^a   Eichelbaum, Michel ^a   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b Epidauros Biotechnologie AG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; AMFEBUTAMONE; BUPROPION HYDROXYLASE; CCAAT ENHANCER BINDING PROTEIN; CYTOCHROME P450 2B6; CYTOSINE; GUANINE; LUCIFERASE; OXYGENASE; THYMINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BASE PAIRING; BINDING SITE; CATALYSIS; CELL STRAIN HEPG2; COMPUTER MODEL; CONTROLLED STUDY; CYP2B6 GENE; DNA DETERMINATION; DNA SEQUENCE; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER CELL; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TATA BOX; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CYTOSINE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; TATA BOX; THYMINE; TRANSCRIPTION INITIATION SITE;

EID: 17844375918     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.008086     Document Type: Article

References (40)

1. Antonarakis SE and the Nomenclature Working Group (1998) Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 11:1-3.
2. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, and Kamataki T (2001) A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 281:1256-1260.
3. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, and Oude Elferink RP (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
4. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, and Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
5. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, and Greenblatt DJ (2001) Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110-119.
6. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, and Buclin T (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73:20-30.
7. Dorko K, Freeswick PD, Bartoli F, Cicalese L, Bardsley BA, Tzakis A, and Nussler AK (1994) A new technique for isolating and culturing human hepatocytes from whole or split livers not used for transplantation. Cell Transplant 3:387-395.
8. Faucette SR, Hawke RL, LeCluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
9. Goodwin B, Moore LB, Stoltz CM, McKee DD, and Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427-431.
10. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, and Court MH (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238.
11. Hirsch-Ernst KI, Schlaefer K, Bauer D, Heder AF, and Kahl GF (2001) Repression of phenobarbital-dependent CYP2B1 mRNA induction by reactive oxygen species in primary rat hepatocyte cultures. Mol Pharmacol 59:1402-1409.
12. Hoffman SM, Nelson DR, and Keeney DS (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11:687-698.
13. Hoffmann M, Mager WH, Scholte BJ, Civil A, and Planta RJ (1992) Analysis of the promoter of the cytochrome P-450 2B2 gene in the rat. Gene Expr 2:353-363.
14. Honkakoski P, Moore R, Gynther J, and Negishi M (1996) Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. J Biol Chem 271:9746-9753.
15. Ingelman-Sundberg M (1999) Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological and clinical pharmacological aspects. Drug Metab Rev 31:449-459.
16. Jakobsson J, Karypidis H, Johansson JE, Roh HK, Rane A, and Ekstrom L (2004) A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians. Pharmacogenomics J 4:245-250.
17. Jean A, Reiss A, Desrochers M, Dubois S, Trottier E, Trottier Y, Wirtanen L, Adesnik M, Waxman DJ, and Anderson A (1994) Rat liver cytochrome P450 2B3: structure of the CYP2B3 gene and immunological identification of a constitutive P450 2B3-like protein in rat liver. DNA Cell Biol 13:781-792.
18. Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, Callahan AM, Hinton ML, Chao J, and Post RM (1995) Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 15:327-333.
19. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, and Brockmoller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
20. Lakso M, Masaki R, Noshiro M, and Negishi M (1991) Structures and characterization of sex-specific mouse cytochrome P-450 genes as members within a large family. Duplication boundary and evolution. Eur J Biochem 195:477-486.
21. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) Expression, J Pharmacol Exp Ther 307:906-922.
22. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
23. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, and Zanger UM (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34-41.
24. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
25. Park Y and Kemper B (1996) The CYP2B1 proximal promoter contains a functional C/EBP regulatory element. DNA Cell Biol 15:693-701.
26. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, and Ingelman-Sundberg M (2001) Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284:455-460.
27. Quandt K, Frech K, Karas H, Wingender E, and Werner T (1995) MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23:4878-4884.
28. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
29. Roy P, Yu LJ, Crespi CL, and Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666.
30. Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29-83.
31. Stephens M, Smith NJ, and Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
32. Suzuki Y, Yamashita R, Nakai K, and Sugano S (2002) DBTSS: database of human transcriptional start sites and full-length cDNAs. Nucleic Acids Res 30:328-331.
33. Svensson US and Ashton M (1999) Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48:528-535.
34. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, and Oka S (2004) Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322-1326.
35. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, and LeCluyse EL (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278:14146-14152.
36. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
37. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988.
38. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, and Yokoi T (2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:329-332.
39. Yamano S, Nhamburo PT, Aoyama T, Meyer UA, Inaba T, Kalow W, Gelboin HV, McBride OW, and Gonzalez FJ (1989) cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28:7340-7348.
40. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, and Idle JR (1996) Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41:13-19.